{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:51:26Z","timestamp":1782769886403,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"crossref","award":["64165"],"award-info":[{"award-number":["64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"crossref","award":["64165"],"award-info":[{"award-number":["64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11883-022-00983-2","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T17:02:46Z","timestamp":1645030966000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?"],"prefix":"10.1007","volume":"24","author":[{"given":"Michal","family":"Vrablik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"T\u016fmov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"33","key":"983_CR1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J."},{"issue":"2","key":"983_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/107424840300800206","volume":"8","author":"E Rizos","year":"2003","unstructured":"Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8(2):127\u201334.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"10","key":"983_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/01.RES.0000102042.83024.CA","volume":"93","author":"MJ Lohse","year":"2003","unstructured":"Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10):896\u2013906.","journal-title":"Circ Res."},{"key":"983_CR4","first-page":"381","volume-title":"Brown adipose tissue","author":"CJ Larson","year":"2019","unstructured":"Larson CJ. Translational pharmacology and physiology of brown adipose tissue in human disease and treatment. In: Pfeifer A, Klingenspor M, Herzig S, editors. Brown adipose tissue. Cham: Springer International Publishing; 2019. p. 381\u2013424."},{"issue":"2","key":"983_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10557-007-6016-4","volume":"21","author":"Q Zhao","year":"2007","unstructured":"Zhao Q, Wu TG, Jiang ZF, et al. Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther. 2007;21(2):85\u201390.","journal-title":"Cardiovasc Drugs Ther."},{"key":"983_CR6","unstructured":"Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman\u2019s: the pharmacological basis of therapeutics. 13th edition ed: McGraw-Hill Education; 2017."},{"key":"983_CR7","unstructured":"Katzung BG. Basic & clinical pharmacology. 14th edition ed. Katzung BG, editor: McGraw- Hill Education; 2018."},{"issue":"3","key":"983_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2710.1989.tb00235.x","volume":"14","author":"MJ Kendall","year":"1989","unstructured":"Kendall MJ. Metoprolol\u2014controlled release, zero order kinetics. J Clin Pharm Ther. 1989;14(3):159\u201379.","journal-title":"J Clin Pharm Ther."},{"issue":"10","key":"983_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","volume":"115","author":"JE Deanfield","year":"2007","unstructured":"Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285\u201395.","journal-title":"Circulation."},{"issue":"5789","key":"983_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","volume":"288","author":"RF Furchgott","year":"1980","unstructured":"Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373\u20136.","journal-title":"Nature."},{"issue":"5","key":"983_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.bjp.0706749","volume":"148","author":"AP Davel","year":"2006","unstructured":"Davel AP, Kawamoto EM, Scavone C, et al. Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation. Br J Pharmacol. 2006;148(5):629\u201339.","journal-title":"Br J Pharmacol."},{"issue":"10","key":"983_CR12","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.jacc.2003.06.011","volume":"42","author":"L Cominacini","year":"2003","unstructured":"Cominacini L, FrattaPasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42(10):1838\u201344.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"983_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/00005344-199106000-00016","volume":"17","author":"YS Gao","year":"1991","unstructured":"Gao YS, Nagao T, Bond RA, et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol. 1991;17(6):964\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"3","key":"983_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00395-017-0617-2","volume":"112","author":"S Al-Gburi","year":"2017","unstructured":"Al-Gburi S, Deussen A, Zatschler B, et al. Sex-difference in expression and function of beta- adrenoceptors in macrovessels: role of the endothelium. Basic Res Cardiol. 2017;112(3):29.","journal-title":"Basic Res Cardiol."},{"key":"983_CR15","doi-asserted-by":"crossref","unstructured":"Grisanti LA, de Lucia C, Thomas TP, et al. Prior beta-blocker treatment decreases leukocyte responsiveness to injury. JCI Insight. 2019;5.","DOI":"10.1172\/jci.insight.99485"},{"issue":"23","key":"983_CR16","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/01.CIR.0000042674.89762.20","volume":"106","author":"T Naruko","year":"2002","unstructured":"Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106(23):2894\u2013900.","journal-title":"Circulation."},{"issue":"3","key":"983_CR17","first-page":"1442","volume":"273","author":"TL Yue","year":"1995","unstructured":"Yue TL, Wang X, Gu JL, et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther. 1995;273(3):1442\u20139.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"983_CR18","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1161\/01.CIR.85.4.1630","volume":"85","author":"M Ferrell","year":"1992","unstructured":"Ferrell M, Fuster V, Gold HK, et al. A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85(4):1630\u20131.","journal-title":"Circulation."},{"issue":"2","key":"983_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0008-6363(00)00253-4","volume":"49","author":"BR Brehm","year":"2001","unstructured":"Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001;49(2):430\u20139.","journal-title":"Cardiovasc Res."},{"issue":"3","key":"983_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341\u201355.","journal-title":"Cell."},{"issue":"8","key":"983_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/01.ATV.12.8.936","volume":"12","author":"M Pataki","year":"1992","unstructured":"Pataki M, Lusztig G, Robenek H. Endocytosis of oxidized LDL and reversibility of migration inhibition in macrophage-derived foam cells in vitro. A mechanism for atherosclerosis regression? Arterioscler Thromb: A J Vasc Biol. 1992;12(8):936\u201344.","journal-title":"Arterioscler Thromb: A J Vasc Biol."},{"issue":"3","key":"983_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0008-6363(99)00235-7","volume":"45","author":"MM Kockx","year":"2000","unstructured":"Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res. 2000;45(3):736\u201346.","journal-title":"Cardiovasc Res."},{"issue":"S2","key":"983_CR23","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1002\/j.1552-4604.1990.tb03510.x","volume":"30","author":"T Linden","year":"1990","unstructured":"Linden T, Camejo G, Wiklund O, et al. Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol. 1990;30(S2):S124\u201331.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"983_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2362.1996.150293.x","volume":"26","author":"G Anfossi","year":"1996","unstructured":"Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996;26(5):353\u201370.","journal-title":"Eur J Clin Invest."},{"issue":"9","key":"983_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1056\/NEJM198108273050907","volume":"305","author":"J Koch-Weser","year":"1981","unstructured":"Koch-Weser J, Frishman WH. Beta-adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305(9):500\u20136.","journal-title":"N Engl J Med."},{"issue":"3","key":"983_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1476-5381.1983.tb10005.x","volume":"79","author":"R Kerry","year":"1983","unstructured":"Kerry R, Scrutton MC. Platelet beta-adrenoceptors. Br J Pharmacol. 1983;79(3):681\u201391.","journal-title":"Br J Pharmacol."},{"issue":"5","key":"983_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bcp.12404","volume":"78","author":"TN Bonten","year":"2014","unstructured":"Bonten TN, Plaizier CE, Snoep JJ, et al. Effect of beta-blockers on platelet aggregation: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;78(5):940\u20139.","journal-title":"Br J Clin Pharmacol."},{"issue":"10","key":"983_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","volume":"11","author":"S Jacob","year":"1998","unstructured":"Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11(10):1258\u201365.","journal-title":"Am J Hypertens."},{"issue":"9","key":"983_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","volume":"13","author":"WH Frishman","year":"2011","unstructured":"Frishman WH, Saunders E. Beta-adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13(9):649\u201353.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"5 Suppl","key":"983_CR30","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","volume":"30","author":"LM Kuyper","year":"2014","unstructured":"\u2022 Kuyper LM, Khan NA. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014;30(5 Suppl):S47-53. Meta-analysis of 21 trials showing differences between atenolol and non-atenolol BBs particularly in the elderly, favoring non-atenolol BBs.","journal-title":"Can J Cardiol."},{"key":"983_CR31","doi-asserted-by":"crossref","unstructured":"Kveiborg B, Hermann TS, Major-Pedersen A, et al. Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes \u2013 a randomized study. Cardiovasc Diabetol. 2010;9:21.","DOI":"10.1186\/1475-2840-9-21"},{"key":"983_CR32","doi-asserted-by":"publisher","unstructured":"Reisin E, Owen J. Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. J Am Soc Hypertens. 2015 Feb;9(2):156-9; quiz 160. https:\/\/doi.org\/10.1016\/j.jash.2014.12.015. Epub 2015 Jan 29. PMID: 25748147.","DOI":"10.1016\/j.jash.2014.12.015"},{"issue":"2","key":"983_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/hs0202.102332","volume":"33","author":"O Wiklund","year":"2002","unstructured":"Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release\/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33(2):572\u20137.","journal-title":"Stroke."},{"issue":"3","key":"983_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1463-1326.2008.00927.x","volume":"11","author":"DSH Bell","year":"2009","unstructured":"Bell DSH, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009;11(3):234\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 5","key":"983_CR35","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1097\/00005344-199006165-00013","volume":"16","author":"R Fogari","year":"1990","unstructured":"Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S76-80.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"Suppl 11","key":"983_CR36","first-page":"S96","volume":"8","author":"HU Janka","year":"1986","unstructured":"Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S96\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"1","key":"983_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1574886313666181029101247","volume":"14","author":"AA Almeman","year":"2019","unstructured":"Almeman AA, Beshir YA, Aldosary AH. Comparison of the effects of metoprolol and bisoprolol on lipid and glucose profiles in cardiovascular patients. Curr Drug Saf. 2019;14(1):27\u201330.","journal-title":"Curr Drug Saf."},{"issue":"4","key":"983_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000229305","volume":"30","author":"A Whaley-Connell","year":"2009","unstructured":"Whaley-Connell A, Habibi J, Johnson M, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol. 2009;30(4):354\u201360.","journal-title":"Am J Nephrol."},{"issue":"10","key":"983_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2165\/00003495-200666100-00007","volume":"66","author":"MD Moen","year":"2006","unstructured":"Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs. 2006;66(10):1389\u2013409 (discussion 410).","journal-title":"Drugs."},{"issue":"6","key":"983_CR40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/AphA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension."},{"issue":"3","key":"983_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pharmthera.2003.09.001","volume":"100","author":"N Toda","year":"2003","unstructured":"Toda N. Vasodilating \u03b2-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100(3):215\u201334.","journal-title":"Pharmacol Ther."},{"issue":"6","key":"983_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/1060028013519591","volume":"48","author":"TL Ripley","year":"2014","unstructured":"Ripley TL, Saseen JJ. \u0392-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014;48(6):723\u201333.","journal-title":"Ann Pharmacother."},{"issue":"13","key":"983_CR43","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","volume":"103","author":"B Hedblad","year":"2001","unstructured":"Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR\/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103(13):1721\u20136.","journal-title":"Circulation."},{"issue":"2","key":"983_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.atherosclerosis.2010.12.031","volume":"215","author":"G Ostling","year":"2011","unstructured":"Ostling G, Goncalves I, Wikstrand J, et al. Long-term treatment with low-dose metoprolol CR\/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis. 2011;215(2):440\u20135.","journal-title":"Atherosclerosis."},{"issue":"23","key":"983_CR45","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1001\/jama.292.23.2849","volume":"292","author":"S Wassertheil-Smoller","year":"2004","unstructured":"Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292(23):2849\u201359.","journal-title":"JAMA."},{"key":"983_CR46","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227\u201336.","journal-title":"JAMA."},{"key":"983_CR47","unstructured":"Kumar, R, Mal, K, Begum, J and Shaukat, F. Comparison of nebivolol and bisoprolol for cardiovascular"}],"updated-by":[{"DOI":"10.1007\/s11883-022-01015-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000}}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-00983-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-00983-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-00983-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T08:48:32Z","timestamp":1666428512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-00983-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-00983-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11883-022-01015-9","asserted-by":"object"}]},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"21 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11883-022-01015-9","URL":"https:\/\/doi.org\/10.1007\/s11883-022-01015-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Vrablik and Dr. Corsini report personal fees from Recordati S.p.A., Milano, Italy, during the conduct of the work. Dr. Tumova has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}